Kairos Pharma, Ltd. (KAPA) Price & Analysis

Compare

98 Followers

KAPA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.40 - $4.00

Previous CloseN/A

Volume680.77K

Average Volume (3M)1.23M

Market Cap

N/A

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.51

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding20,743,765

10 Day Avg. Volume784,543

30 Day Avg. Volume1,228,799

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$8.00

Price Target Upside534.92% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPositive safety data from the P2 prostate cancer trial has led to a significant increase in the company's share price.

Financial PositionKairos has a $6.7M pro forma cash balance, and with a quarterly burn rate of ~$0.6M, the company should be funded into 2026.

Research AdvancementsPositive preclinical data for KROS101 at an ongoing ASCO meeting boosts confidence in the company's research advancements.

Bears Say

EarningsKairos filed its 10-Q and reported 2Q25 results with a net loss of ($1.4M) and ended the period with $3.1M in cash, which management expects to provide runway into 2026.

Financial PerformanceKairos announced 2Q25 financial results, posting EPS of ($0.08), compared to our estimate of ($0.06), and consensus of ($0.05).

Kairos Pharma, Ltd. News

Kairos Pharma management to meet with Maxim

Meeting to be held on August 6 hosted by Maxim. Published first on TheFly – the ultimate source...

25d ago

KAPA

Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Kairos Pharma, Ltd.. The associated price...

15d ago

KAPA

Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kairos Pharma, Ltd.,...

16d ago

KAPA

Why Is Kairos Pharma Stock (KAPA) Up 170% Today?

Kairos Pharma stock rallied on Tuesday after it posted positive interim safety results from a clinical trial. ...

1M ago

KAPA

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Traders looking for all of Tuesday’s hottest stock market news will find it at TipRanks! ...

2M ago

AMD

Promising Potential for Kairos Pharma’s ENV-105: Positive Safety Profile and Efficacy Outlook

Kairos Pharma, Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

2M ago

KAPA

Kairos Pharma Announces Positive Phase 2 Trial Results

Kairos Pharma, Ltd. ( ($KAPA) ) has provided an update. On July 15, 2025, Kairos Pharma, Ltd. announced...

2M ago

KAPA

Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial

Kairos Pharma (KAPA) announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients...

2M ago

KAPA

Kairos Pharma Enhances U.S. Investor Relations Strategy

Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On June 10, 2025, Kairos Pharma, Ltd. entered...

3M ago

KAPA

Promising Developments in Oncology Drive Buy Rating for Kairos Pharma

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Kairos Pharma, Ltd....

3M ago

KAPA

Kairos Pharma Presents Promising KROS101 Data at ASCO 2025

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an update. Kairos Pharma Ltd. announced the presentation of new...

3M ago

KAPA

Kairos Pharma files to sell 16.29M shares of common stock for holders

06:05 EDT Kairos Pharma (KAPA) files to sell 16.29M shares of common stock for holders Published first on...

4M ago

KAPA

Kairos Pharma: Promising Oncology Pipeline and Strategic Advancements Drive Buy Rating

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kairos Pharma, Ltd. (KAPA – Research Report)...

5M ago

KAPA

Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

5M ago

KAPA FAQ

What was Kairos Pharma, Ltd.’s price range in the past 12 months?

Kairos Pharma, Ltd. lowest stock price was $0.40 and its highest was $4.00 in the past 12 months.

What is Kairos Pharma, Ltd.’s market cap?

Currently, no data Available

When is Kairos Pharma, Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kairos Pharma, Ltd.’s earnings last quarter?

Currently, no data Available

Is Kairos Pharma, Ltd. overvalued?

According to Wall Street analysts Kairos Pharma, Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kairos Pharma, Ltd. pay dividends?

Kairos Pharma, Ltd. does not currently pay dividends.

What is Kairos Pharma, Ltd.’s EPS estimate?

Kairos Pharma, Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kairos Pharma, Ltd. have?

Kairos Pharma, Ltd. has 20,743,765 shares outstanding.

What happened to Kairos Pharma, Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kairos Pharma, Ltd.?

Currently, no hedge funds are holding shares in KAPA

Company Description

Kairos Pharma, Ltd.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Kairos Pharma, Ltd. (KAPA) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

KAPA Stock 12 Month Forecast

Average Price Target

$8.00

▲(534.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","-1":"-$1","2.5":"$2.5","9.5":"$9.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.5,6,9.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.92,1.7723076923076924,2.624615384615385,3.476923076923077,4.32923076923077,5.181538461538461,6.033846153846154,6.886153846153846,7.7384615384615385,8.590769230769231,9.443076923076923,10.295384615384615,11.147692307692308,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.92,1.4646153846153847,2.0092307692307694,2.5538461538461537,3.0984615384615384,3.643076923076923,4.187692307692307,4.7323076923076925,5.276923076923077,5.821538461538461,6.366153846153846,6.9107692307692306,7.455384615384615,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.92,1.156923076923077,1.393846153846154,1.6307692307692307,1.8676923076923078,2.1046153846153848,2.3415384615384616,2.5784615384615384,2.8153846153846156,3.0523076923076924,3.289230769230769,3.526153846153846,3.763076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.46,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >